An inexpensive, low-invasive method for detecting ESR1 mutations in breast cancer patients on hormone therapy is very relevant because it could help in identifying patients who may benefit from potential therapeutic options, such as Elacestrant [32], in addition to assessing resistance to hormone therapy. Here, ESR1 is linked to breast carcinoma.